Vivos Therapeutics (VVOS) Fireside Chat summary

Introduction and agenda

• Fireside chat hosted by a senior healthcare analyst with the CEO and CFO, focusing on sleep-related breathing disorders and company strategy.

• Disclosures regarding forward-looking statements and non-GAAP financial measures were provided at the outset.

Background and experience of the speaker

• CEO described the company’s mission to address the global epidemic of obstructive sleep apnea, affecting over 1 billion people.

• Emphasis on a novel, root-cause approach to treatment, aiming for affordability and accessibility.

Current industry trends

• Traditional reliance on dentists for distribution was limited by their reluctance to address medical conditions.

• The company received unprecedented FDA clearance in November 2023 to treat all levels of sleep apnea, including severe cases.

• CPAP has been the entrenched gold standard for OSA, but recent recalls and adverse events have created opportunities for alternatives.

• Technological advances have reduced the cost and barriers to sleep apnea diagnosis, increasing patient access.